MedTrace Logo

Brain Derived Neurotropic Factor Response to Aerobic Exercise Intensity in Depressive Patients.

NCT02741622 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2018-12-04

No results posted yet for this study

Summary

Acute aerobic exercise improves affective stats in patients with mental illnesses. Brain derived neurotropic factor (BDNF) may be a biological mechanism that contributes to the affective benefits. The magnitude of the increase of serum BDNF might be exercise intensity dependent, but no study has compared low high-aerobic-intensity training at 90-95 % of the maximal heart rate (HRmax) with long-slow-distance training at 70 % of the HRmax in patients with depression.

The aim of this study is to compare changes in serum BDNF levels after high-aerobic-intensity training and long-slow-distance training in a intra-individual design in patients suffering from depression. The results will give indications of a possible difference in BDNF response between aerobic intensities and may be uses as pilot data for calculating sample size.

Conditions

  • Depressive Disorder
  • Depressive Disorder, Major

Interventions

BEHAVIORAL

High aerobic intensity training (HIT)

One training session, high aerobic intensity training (HIT) at 90-95 % of the maximal heart rate (HRmax)

BEHAVIORAL

Long slow distance training (LSD)

One training session, long slow distance training (LSD) at 70 % of the HRmax

Sponsors & Collaborators

  • Norwegian University of Science and Technology

    collaborator OTHER

  • St. Olavs Hospital

    lead OTHER

Principal Investigators

  • Pål Sandvik, MD · St.Olavs University Hospital, Østmarka

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02741622 on ClinicalTrials.gov